Abstract
Introduction
Anemia with histopathologic and laboratory evidence of ineffective erythropoiesis is a hallmark of myelodysplastic syndromes (MDS) and of juvenile and chronic myelomonocytic leukemia (JMML and CMML), which are classified as MDS/myeloproliferative disorder (MDS/MPD) overlap diseases 2, 3 . In addition to monocytic myeloproliferation, JMML and CMML are characterized by anemia with splenomegaly, extramedullary hematopoiesis, and variable degrees of erythroid dysplasia [4] [5] [6] [7] .
Deregulated signaling pathways play a fundamental role in the pathogenesis of myeloid malignancies 8 . Mutations in NRAS or KRAS2 are among the most common genetic lesions found in acute myeloid leukemia (AML), MDS, and MPD. Ras proteins are signal switch molecules that regulate growth and differentiation by cycling between an active guanosine triphosphate (GTP)-bound state (Ras•GTP) and an inactive guanosine diphosphate (GDP)-bound state.
Oncogenic Ras proteins accumulate in the GTP-bound conformation due to defective intrinsic GTP hydrolysis and resistance to GTPase activating proteins (GAPs) [9] [10] [11] . In addition to oncogenic RAS mutations, Ras signaling is deregulated in myeloid malignancies by alternative genetic mechanisms that include the BCR-ABL fusion, PTPN11 mutations, and NF1 inactivation [12] [13] [14] .
Expressing oncogenic RAS alleles with retroviral vectors inhibits differentiation of erythroid progenitors in vitro, suggesting that hyperactive Ras has a direct pathogenic role in the anemia that occurs in MDS and in MDS/MPD overlap disorders 15, 16 . However, retroviral transduction requires ex vivo manipulation of primary cells and results in supra-physiologic Ras protein levels that could contribute to these phenotypes 17 . Somatic activation of oncogenic KRas G12D results in a fatal monocytic MPD in Mx1-Cre, Kras G12D mice that is associated with anemia and splenomegaly with extramedullary hematopoiesis 18, 19 . Here we show that expressing Kras G12D from its endogenous promoter induces ineffective erythropoiesis in vivo, with an apparent block in differentiation at the proerythroblast stage.
Study Design
Mice. Mice were maintained in the sterile UCSF animal care facility and were fed pelleted chow and acidified water ad libitum. The experimental procedures were approved by the UCSF injection and hematologic studies were performed as described 18 .
Erythropoietin (EPO) Levels and Flow Cytometry. Serum EPO was measured by ELISA (Quantikine MEP00, R&D Systems). Staining for CD71, TER119, 5'-bromodeoxyuridine (BrdU), and with Annexin V and 7-amino-actinomycin D were performed using commercial fluorochrome-conjugated reagents following manufacturer's instructions (BD Pharmingen).
Mice were injected intraperitoneally with BrdU (150 mg/kg) one hour prior to harvesting tissue for analysis.
In Vitro Cultures. Erythroid differentiation assays were performed according to published methodologies 15 with the addition of a 4-day preincubation in IL-11 (100 ng/mL), SCF (100 ng/mL), Flt-3 (50 ng/mL), IL-6 (20 ng/mL) and IFNβ (400 U/mL; all from R&D Systems) to induce Mx1-Cre expression. Progenitor colonies were enumerated in methylcellulose medium (M3234; StemCell Technologies) supplemented with recombinant human EPO (R&D Systems) and counted after incubation for 2-3 (CFU-E) or 7 (BFU-E) days.
Results and Discussion
Mx1-Cre, Kras G12D mice develop fatal monocytic MPD on both F1 C57BL/6 x 129Sv/Jae and inbred C57BL/6 backgrounds (Braun et al. 18 and data not shown). Although myeloid proliferation is modestly attenuated in C57BL/6 mice, there is no difference in time of onset or severity of anemia in these strains. Blood smears show polychromasia and reticulocytosis, with hypochromia and anisopoikilocytosis in moribund animals. Serum EPO levels are elevated in proportion to anemia, consistent with the histopathologic features suggestive of ineffective erythropoiesis ( Figure 1A ). Cre, Kras G12D mice to JMML, which is characterized by BFU-E that exhibit a degree of spontaneous growth as well as growth factor hypersensitivity 7, 20 .
We examined bone marrow cells and splenocytes from anemic Mx1-Cre, Kras G12D mice by flow cytometry to investigate later stages in erythroid differentiation (Figure 2A ). These studies revealed normal numbers of early erythroid cells in bone marrow (CD71  hi TER119 -/low , corresponding to proerythroblasts and some CFU-E 1 ), but a paucity of all the more mature TER119 hi populations (Regions II-IV, Figure 2A and Supplementary , support the idea that effects on erythroid differentiation vary with the degree and duration of Ras activation.
We find that K-Ras G12D causes anemia, at least in part, through inhibitory effects on erythroid differentiation. Our data support the hypothesis that hyperactive Ras directly contributes to ineffective erythropoiesis and anemia in some patients with MDS and MDS/MPD overlap disorders, in whom transfusion dependence is a major morbidity 25 . In vitro data implicate aberrant MEK activity downstream of Ras•GTP in the erythroid differentiation arrest induced by oncogenic Ras 26 . Pharmacologic inhibitors of MEK, which are being developed as potential cancer agents, might therefore ameliorate the anemia seen in JMML, CMML, and in some patients with MDS. Mx1-Cre, Kras G12D mice are a robust preclinical platform for testing this new therapeutic strategy.
